MedTrace Logo

Safety Study of SRX251 Capsules in Healthy Female Volunteers

NCT00461370 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2008-03-13

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of SRX251 when given orally. The amount of SRX251 in the blood will also be measured. Healthy women, ages 18-50 years who have been surgically sterilized by tubal ligation, will be enrolled in this study.

Conditions

  • Healthy

Interventions

DRUG

SRX251

Sponsors & Collaborators

  • Azevan Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Benno G Roesch, MD · Advanced Biomedical Research, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2007-08-31
Completion
2007-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00461370 on ClinicalTrials.gov